Gloria earned her PhD in 2014 from the University of Wisconsin. She is a postdoctoral fellow in the lab of Professor Marc Vidal at Dana-Farber Cancer Institute and is investigating the functional significance of alternative splicing at proteome scale. Alternative splicing is frequently misregulated during carcinogenesis, contributing to rewiring of cellular pathways that drive proliferation, apoptosis, and other hallmarks of cancer. Much knowledge of splicing stems from studies on differential expression of alternatively spliced mRNAs rather than on protein function. Consequently, there is a large gap in our knowledge of the function and significance of alternatively spliced proteins in normal and cancer biology, especially on a proteome-wide scale. The Center for Cancer Systems Biology at Dana-Farber Cancer Institute recently mapped the first protein isoform interactome, demonstrating that alternative isoforms are involved in diverse organizational, functional, and cross-tissue network dynamics. Remarkably, two isoforms from the same gene can be functionally just as different from each other as distinct proteins encoded by two separate genes. Expanding upon the original isoform interactome study, Gloria has begun work towards empirically building and analyzing the first cancer-specific isoform interaction network. This project will be the first global picture of the consequences and functional effects of aberrant splicing in cancer.
Yang X, Coulombe-Huntington J, Kang S, Sheynkman GM, Hao T, Richardson A, Sun S, Yang F, Shen YA, Murray RR, Spirohn K, Begg BE, Duran-Frigola M, MacWilliams A, Pevzner SJ, Zhong Q, Trigg SA, Tam S, Ghamsari L, Sahni N, Yi S, Rodriguez MD, Balcha D, Tan G, Costanzo M, Andrews B, Boone C, Zhou XJ, Salehi-Ashtiani K, Charloteaux B, Chen AA, Calderwood MA, Aloy P, Roth FP, Hill DE, Iakoucheva LM, Xia Y, Vidal M. Widespread Expansion of Protein Interaction Capabilities by Alternative Splicing. Cell. 2016 Feb 11;164(4):805-17.
Continue reading →